| EPE1002 | Improving the precision of subnational AGYW risk estimates in South Africa and Côte d’Ivoire | E-poster | Innovations in data collection, monitoring and evaluation |
| EPB0194 | Improving the safety of clients on antiretroviral therapy through Drug Use Evaluations (DUE) to manage adverse drug events at six ART sites in the Oromia region of Ethiopia | E-poster | Clinical complications of HIV and antiretroviral therapy |
| EPC0492 | Improving viral load coverage and sustaining high viral load suppression amidst operational challenges in Burundi | E-poster | Cascades of HIV care and treatment |
| MOPEE28 | Improving viral load suppression among children aged 0-14 years through community ART distribution in rural Uganda: lessons from Anyeke HCIV | Poster exhibition | Implementation science and scale up of treatment |
| OAA0203 | In vivo genome engineering of human T cells results in ART-free control of HIV-1 in humanized mice | Oral abstract session with live Q&A | Novel treatment and prevention strategies |
| EPE0803 | Incentivized peer referral to increase reach of pharmacy-delivered PrEP and PEP services: findings from a pilot study extension | E-poster | Implementation science and scale up of prevention |
| EPB0231 | Incidence and types of Adverse Drug Reactions to first-line antiretroviral therapy in Nigeria | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0204 | Incidence of infections across Islatravir clinical development programs | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0158 | Incidence of occult hepatitis B virus among people living with HIV in Botswana | E-poster | Co-infections (including opportunistic infections) |
| EPC0358 | Incident hypertension in adults initiating tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis: analysis of data from an integrated health system in California | E-poster | HIV prevention research |